Urogen Pharma (URGN)
(Real Time Quote from BATS)
$13.28 USD
-0.27 (-1.99%)
Updated May 31, 2024 03:06 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
URGN 13.28 -0.27(-1.99%)
Will URGN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for URGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for URGN
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
URGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
Other News for URGN
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
UroGen Pharma price target lowered by $2 at Oppenheimer, here's why
Urogen Pharma (URGN) Gets a Buy from Oppenheimer
UroGen Pharma Holds Steady Amidst Financial Underperformance and Anticipated Study Results
Buy Rating Affirmed for Urogen Pharma as UGN-102 Progresses Towards FDA Approval and Market Success